Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 23;14(2):86-91.
doi: 10.17925/HI.2020.14.2.86. eCollection 2020.

The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions

Gunasekaran Sengottuvelu  1 , Vijay Kumar  2 , Ashok Seth  2
Affiliations
Review

The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions

Gunasekaran Sengottuvelu et al. Heart Int. .

Abstract

Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.

Keywords: Transcatheter aortic valve implantation; balloon-expandable; newer-generation transcatheter heart valve; severe aortic stenosis; transcatheter heart valve.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Gunasekaran Sengottuvelu is the proctor for Myval THV technology and has received honoraria from Meril Life Sciences Pvt. Ltd., India. Ashok Seth is the external scientific advisor to Meril Life Sciences Pvt. Ltd., India, the principal investigator of MyVal-1 Study and proctor for Myval THV technology, and has received honoraria from Meril Life Sciences Pvt. Ltd., India. Vijay Kumar has no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. The Myval™ transcatheter heart valve system
Figure 2:
Figure 2:. Schematic representation of crimped Myval™ transcatheter heart valve system
Figure 3:
Figure 3:. Navigator™ – the delivery system of Myval transcatheter heart valve system
Figure 4:
Figure 4:. Aortogram showing severe calcific aortic stenosis
Figure 5:
Figure 5:. Myval transcatheter heart valve in position with alternating dark and light bands visible
Figure 6:
Figure 6:. Implantation of the valve
Figure 7:
Figure 7:. Valve in position, no paravalvular leak on aortogram
See this image and copyright information in PMC

References

    1. Prendergast BD, Baumgartner H, Delgado V. et al. Transcatheter heart valve interventions: where are we? Where are we going? Eur Heart J. 2019;40:422–40. - PubMed
    1. Webb JG, Wood DA. Current status of transcatheter aortic valve replacement. J Am Coll Cardiol. 2012;60:483–92. - PubMed
    1. Iung B, Cachier A, Baron G. et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714–20. - PubMed
    1. Varadarajan P, Kapoor N, Bansal RC. et al. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: Results from a cohort of 277 patients aged > or =80 years. Eur J Cardiothorac Surg. 2006;30:722–7. - PubMed
    1. Cribier A, Eltchaninoff H, Bash A. et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8. - PubMed

LinkOut - more resources